LFCR (Lifecore Biomedical, Inc.) Stock Financials & Earnings | Market Cap Arena

LFCR (Lifecore Biomedical, Inc.) Stock Financials & Earnings | Market Cap Arena

LFCRLifecore Biomedical, Inc.

Mkt Cap$267M

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Revenue (TTM)$135M

Net Income (TTM)-$32M

EPS (TTM)-$1.07

Free Cash Flow (TTM)-$10M

Gross Margin31.6%

Op. Margin-6.5%

Net Margin-24.0%

FCF Margin-7.1%

P/S Ratio (TTM)2.0x

P/E Ratio (TTM)—

YoY Rev Growth+5.3%

Employees—

Earnings Reports

Next: Q2 2026 · Mar 16

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q2 23	$22M	$6M	-$5M
Q3 23	$27M	$9M	-$7M
Q4 23	$26M	$8M	-$1M
Q1 24	$25M	$3M	-$9M
Q2 24	$30M	$10M	-$1M
Q3 24	$36M	$12M	-$895K
Q4 24	$38M	$17M	$2M
Q1 25	$25M	$5M	-$12M
Q2 25	$33M	$11M	-$2M
Q3 25	$35M	$10M	-$9M
Q4 25	$36M	$14M	$5M
Q1 26	$31M	$8M	-$3M

Valuation

Quarter	P/S	P/E
Q2 23	2.0x	—
Q3 23	2.2x	—
Q4 23	2.7x	—
Q1 24	2.7x	—
Q2 24	2.5x	—
Q3 24	2.3x	—
Q4 24	2.1x	22.2x
Q1 25	2.1x	40.8x
Q2 25	2.0x	—
Q3 25	2.0x	—
Q4 25	2.1x	—
Q1 26	2.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 23	-$2M	-$6M
Q3 23	-$15M	-$22M
Q4 23	-$272K	-$9M
Q1 24	-$8M	-$13M
Q2 24	$1M	-$3M
Q3 24	-$1M	-$8M
Q4 24	$9M	$6M
Q1 25	-$643K	-$4M
Q2 25	-$6M	-$9M
Q3 25	$1M	-$4M
Q4 25	$5M	$3M
Q1 26	$2M	$25K

Capital Expenditures

CapEx

Quarter	CapEx
Q2 23	$4M
Q3 23	$7M
Q4 23	$9M
Q1 24	$5M
Q2 24	$4M
Q3 24	$6M
Q4 24	$3M
Q1 25	$3M
Q2 25	$2M
Q3 25	$5M
Q4 25	$2M
Q1 26	$2M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 23	-49.7%	-30.8%
Q3 23	-29.0%	-28.1%
Q4 23	-46.4%	-69.1%
Q1 24	+3.4%	+22.7%
Q2 24	+37.9%	+16.2%
Q3 24	+34.5%	+10.7%
Q4 24	+48.5%	+33.6%
Q1 25	+0.7%	+9.5%
Q2 25	+8.0%	+9.1%
Q3 25	-1.5%	+20.7%
Q4 25	-3.8%	-12.9%
Q1 26	+25.9%	-5.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$816K	3.2%
Q1 24	$2M	6.3%
Q2 24	$2M	5.2%
Q3 24	$1M	4.2%
Q4 24	$2M	4.2%
Q1 25	$2M	9.8%
Q2 25	$3M	10.4%
Q3 25	$0	0.0%
Q4 25	$2M	5.0%
Q1 26	$2M	7.7%

OpEx Breakdown

Quarter	R&D	SG&A
Q2 23	$2M	$8M
Q3 23	$2M	$10M
Q4 23	$3M	$8M
Q1 24	$2M	$9M
Q2 24	$2M	$9M
Q3 24	$2M	$10M
Q4 24	$2M	$12M
Q1 25	$2M	$14M
Q2 25	$2M	$11M
Q3 25	$2M	$10M
Q4 25	$2M	$9M
Q1 26	$2M	$9M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 23	$7M	$0	$7M
Q3 23	$3M	$0	$3M
Q4 23	$19M	$0	$19M
Q1 24	$9M	$0	$9M
Q2 24	$3M	$0	$3M
Q3 24	$3M	$0	$3M
Q4 24	$8M	$0	$8M
Q1 25	$6M	$0	$6M
Q2 25	$9M	$0	$9M
Q3 25	$5M	$0	$5M
Q4 25	$8M	$0	$8M
Q1 26	$19M	$0	$19M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q2 23	30M	+2.4%
Q3 23	30M	+0.0%
Q4 23	30M	+0.1%
Q1 24	30M	+0.3%
Q2 24	36M	+19.8%
Q3 24	37M	+0.5%
Q4 24	31M	-16.5%
Q1 25	31M	+1.0%
Q2 25	34M	+11.4%
Q3 25	37M	+7.7%
Q4 25	37M	+0.0%
Q1 26	37M	+1.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	—	—
FY 16	—	—
FY 17	—	—
FY 18	—	—
FY 19	—	—
FY 20	—	—
FY 21	—	—
FY 22	—	—
FY 23	$225K	459
FY 24	$245K	524
FY 25	$317K	406